Pioglitazone Solid Dispersion System Prepared by Spray Drying Method: In Vitro and In Vivo Evaluation

References

1. 1.↵
   1. Gupta M. K.,
   2. Vanwert A.,
   3. Bonger R. H

   . Formation of physically stable amorphous drugs by milling with Neusilin. J. Pharm. Sci. 2003, 92 (3), 536–551.

   OpenUrlPubMed
2. 2.↵
   1. Corrigan O. I

   . Thermal analysis of spray dried products. Thermochimica Acta 1995, 248, 245–258.

   OpenUrl
3. 3.↵
   1. Gajare P.,
   2. Patil C.,
   3. Kalyane N.,
   4. Pore Y

   . Effect of hydrophilic polymers on pioglitazone complexation with hydrorypropyl-β-cyclodextrin. Digest Journal of Nanomaterials and Biostructures 2009, 4 (4), 891–897.

   OpenUrl
4. 4.↵
   1. Prajapati S. T.,
   2. Gohel M. C.,
   3. Patel L. D

   . Studies to enhance dissolution properties of carbamazepine. Indian J. Pharm. Sci. 2007, 69 (3), 427–430.

   OpenUrl
5. 5.↵
   1. Ambike A.,
   2. Mahadik K.,
   3. Paradkar A

   . Spray-dried amorphous solid dispersions of Simvastatin, a low Tg drug: in vitro and in vivo evaluations. Pharm. Res. 2005, 22 (6), 990–998.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Chauhan B.,
   2. Shimpi S.,
   3. Paradkar A

   . Preparation and characterization of etoricoxib solid dispersion using lipid carriers by spray drying technique. AAPS PharmSciTech 2005, 6 (3), E405–E409.

   OpenUrlPubMed
7. 7.↵
   1. Hu J.,
   2. Rogers T. L.,
   3. Brown J.,
   4. Young T.,
   5. Johnstan K. P.,
   6. Williams R. O

   . Improvement of dissolution rates of poorly water soluble APIs using novel spray freezing into liquid technology. Pharm. Res. 2002, 19 (9), 1278–1284.

   OpenUrlPubMed
8. 8.↵
   1. Fini A.,
   2. Roderguez C.,
   3. Cavallari C.,
   4. Albertini B.,
   5. Passerini N

   . Ultrasound compacted and spray congealed indomethacin/polyethylene glycol systems. Int. J. Pharm. 2002, 247 (1–2), 11–22.

   OpenUrlPubMed
9. 9.↵
   1. Brietenbach J.,
   2. Berndl G.,
   3. Neumann J.,
   4. Rosenber J.,
   5. Simon O.,
   6. Zeidler J

   . Solid dispersion by integrated melt extrusion systems. Proc. Int. Symp. Control Rel. Bioact. Mater. 1998, 25, 804–805.

   OpenUrl
10. 10.↵
    1. Damian F.,
    2. Blaton N.,
    3. Naesens L.,
    4. Balzarini J.,
    5. Kinget R.,
    6. Augustijns P.,
    7. Van den Mooter G

    . Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14. Eur. J. Pharm. Sci. 2000, 10 (4), 311–322.

    OpenUrlPubMed
11. 11.↵
    1. Abdul-Fattah A. M.,
    2. Bhargava H. N

    . Preparation and in vitro evaluation of solid dispersions of halofantrine. Int. J. Pharm. 2002, 235 (1–2), 17–33.

    OpenUrlPubMed
12. 12.↵
    1. Sethia S.,
    2. Squillante E

    . Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods. Int. J. Pharm. 2004, 272 (1–2), 1–10.

    OpenUrlPubMed
13. 13.↵
    1. Doshi D. H.,
    2. Ravis W. R.,
    3. Betageri G. V

    . Carbamazepine and polyethylene glycol solid dispersions: preparation, in vitro dissolution, and characterization. Drug Dev. Ind. Pharm. 1997, 23 (12), 1167–1176.

    OpenUrl
14. 14.↵
    1. Kazuto O.,
    2. Masatoshi M.,
    3. Rinta I.,
    4. Mituru Y.,
    5. Norio O.,
    6. Tasuku N

    . Dissolution mechanism and rate of solid dispersion particles of nilvadipine with hydroxypropyl methylcellulose. Int. J. Pharm. 1997, 159 (1), 85–93.

    OpenUrl
15. 15.↵
    1. Hirasawa N.,
    2. Ishise S.,
    3. Miyata H.,
    4. Danjo K

    . An attempt to stabilize nilvadipine solid dispersion by the use of ternary systems. Drug Dev. Ind. Pharm. 2003, 29 (9), 997–1004.

    OpenUrlPubMed
16. 16.↵
    1. Karavas E.,
    2. Ktistis G.,
    3. Xenakis A.,
    4. Georgarakis E

    . Miscibility behavior and formation mechanism of stabilized felodipine-polyvinylpyrrolidone amorphous solid dispersions. Drug Dev. Ind. Pharm. 2005, 31 (6), 473–89.

    OpenUrlPubMed
17. 17.↵
    1. Hirasawa N.,
    2. Danij K.,
    3. Haruna M.,
    4. Otsuka A

    . Physicochemical characterization and drug release studies of naproxen solid dispersion using lactose as a carrier. Chem. Pharm. Bull. 1998, 46 (6), 1027–1030.

    OpenUrl
18. 18.↵
    1. Rawat S.,
    2. Jain S. K

    . Rofecoxib-beta-cyclodextrin inclusion complex for solubility enhancement. Pharmazie 2003, 58 (9), 639–641.

    OpenUrlPubMed
19. 19.↵
    1. LaMonte M. J.,
    2. Blair S. N.,
    3. Church T. S

    . Physical activity and diabetes prevention. J. Appl. Physiol. 2005, 99 (3), 1205–1213.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Hancock B. C.,
    2. Zografi G

    . Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 1997, 86 (1), 1–12.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.↵
    1. Lian Y

    . Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv. Drug Del. Rev. 2001, 48 (1), 27–42.

    OpenUrlPubMed
22. 22.↵
    1. Paradkar A.,
    2. Ambike A.,
    3. Jadhav B. K.,
    4. Mahadik K. R

    . Characterization of curcumin-PVP solid dispersion obtained by spray drying. Int. J. Pharm. 2004, 271 (1–2), 281–286.

    OpenUrlPubMed
23. 23.↵
    1. Ambike A. A.,
    2. Mahadik K. R.,
    3. Paradkar A

    . Stability study of amorphous valdecoxib. Int. J. Pharm. 2004, 282 (1–2), 151–162.

    OpenUrlPubMed
24. 24.↵
    1. Ketkar A. R.,
    2. Patil V. B.,
    3. Paradkar A. R

    . Computer Aided Exploratory Data Analysis Model Fitting for Dissolution Kinetics: 4^th International Symposium on Advances in Technology and Business Potential of New Drug Delivery System. Controlled Release Society Indian Chapter, Mumbai, India, 2002, p 62.
25. 25.↵
    1. Badole S. L.,
    2. Bodhankar S. L

    . Concomitant administration of petroleum ether extract of the stem bank of Pongamia pinnata (L.) Pierre with synthetic oral hypoglycemic drugs in alloxan-induced diabetic mice. Eur. J. Integrative Medicine 2009, 1 (2), 73–79.

    OpenUrl
26. 26.↵
    1. Selvam P

    . Evaluation of antidiabetic activity of a polyherbal formulation in alloxan induced diabetic rats. Int. J. Pham. Sci. Res. 2010, 1 (9), 82–87.

    OpenUrl
27. 27.↵
    1. Seedher N.,
    2. Kanojia M

    . Co-solvent solubilization of some poorly-soluble antidiabetic drugs. Pharm. Dev. Technol. 2009, 14 (2), 185–192.

    OpenUrlPubMed
28. 28.↵
    1. Bhole P. G.,
    2. Patil V. R

    . Enhancement of water solubility of felodipine by preparing solid dispersion using poly-ethylene glycol 6000 and poly-vinyl alcohol. Asian J Pharm. 2009, 3 (3), 240–244.

    OpenUrl
29. 29.↵
    1. Karataş A.,
    2. Yüksel N.,
    3. Baykara T

    . Improved solubility and dissolution rate of piroxicam using gelucire 44/14 and labrasol. Farmaco 2005, 60 (9), 777–782.

    OpenUrlPubMed
30. 30.↵
    1. Taylor L. S.,
    2. Zografi G

    . Spectroscopic characterization of interaction between PVP and indomethacin in amorphous molecular dispersions. Pharm. Res. 1997, 14 (12), 1691–1698.

    OpenUrlPubMed
31. 31.↵
    1. Won D. H.,
    2. Kim M. S.,
    3. Lee S.,
    4. Park J. S.,
    5. Hwang S. J

    . Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process. Int. J. Pharm. 2005, 301 (1–2), 199–208.

    OpenUrlPubMed
32. 32.↵
    1. Patel R. P.,
    2. Patel M. M

    . Physicochemical characterization and dissolution study of solid dispersions of Lovastatin with polyethylene glycol 4000 and polyvinylpyrrolidone K30. Pharm. Dev. Technol. 2007, 12 (1), 21–33.

    OpenUrlPubMed